Cariprazine Publications 2006-2019

Non-clinical

Chemistry
Physico-chemical characterization of a novel group of dopamine D3/D2 receptor ligands, potential atypical antipsychotic agents
Deák K, Takács-Novák K, Kapás M, Vastag M, Tihanyi K, Noszál B

Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D3/D2 receptors

Neurochemistry
Cariprazine (RGH-188) is a dopamine D3 receptor preferring D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile
J Pharmacol Exp Ther 333: 328-340, 2010

Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography
Psychopharmacology 218: 579-587, 2011

In vitro and in vivo comparison of [3H](+)-PHNO and [3H]-raclopride binding to rat striatum and lobes 9 and 10 of the cerebellum: A method to distinguish dopamine D3 from D2 receptor sites
Kiss B, Horti F, Bobok A
Synapse 65: 467-478, 2011

Synapse 67: 258-264, 2013

Long-Term Effects of Cariprazine Exposure on Dopamine Receptor Subtypes
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrums 19: 268-277, 2014

Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine Open access
Choi YK, Adham N, Kiss B, Gyertyán I, Tarazi FI
CNS Spectrums, 22: 484-494, 2017

Effects of cariprazine on extracellular levels of glutamate, GABA, dopamine, noradrenaline and serotonin in the medial prefrontal cortex in the rat phencyclidine model of schizophrenia studied by microdialysis and simultaneous recordings of locomotor activity Open access
Kehr J, Yoshitake T, Ichinose F, Yoshitake S, Kiss B, Gyertyán I, Adham N

Pharmacology


The effects of cariprazine and aripiprazole on PCP-induced deficits on attention assessed in the 5-choice serial reaction time task. Barnes S, Young J, Markou A, Adham N, Gyertyán I, Kiss B. *Psychopharmacology* **235**: 1403-1414, 2018


**Pharmacokinetic**


**Clinical**

**Schizophrenia**


Cariprazine as monotherapy for the treatment of predominant negative symptoms in patients with schizophrenia: A randomized, double-blind, active-comparator controlled trial

Open access at Richter website
Lancet **389**: 1103-1113, 2017

Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study
CNS Spectrums **23**: 39-50, 2018

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: Results from a 48-week, open-label extension study
Durgam S, Greenberg WM, Li D, Lu K, Laszlovszky I, Németh G, Migliore R, Volk S
Psychopharmacology **234**: 199-209, 2017

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies
Earley W, Durgam S, Lu K, Laszlovszky I, Debelle M, Kane JM
Int Clin Psychopharmacol **32**: 319-328, 2017

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: A post hoc pooled analysis
BMC Psychiatry **17**: 305, 2017

Negative Symptoms of Schizophrenia: Constructs, Burden, and Management

Open access
Barabássy A, Szatmári B, Laszlovszky I, Németh G
Psychotic Disorders: An Update; Edited by Federico Durbano, IntechOpen, pp. 43-62, 2018
ISBN 978-953-51-5976-6; [http://dx.doi.org/10.5772/intechopen.73300](http://dx.doi.org/10.5772/intechopen.73300)

Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: A post hoc analysis of pooled data
Schizophr Res **204**: 282-288, 2019

Long-term remission with cariprazine treatment in patients with schizophrenia: A post hoc analysis of a randomized, double-blind, placebo-controlled, relapse prevention trial
Correll CU, Potkin SG, Zhong Y, Harsányi J, Szatmári B, Earley W
J Clin Psychiatry **80**: 18m12495, 2019

Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies
Eur Neuropsychopharmacol **29**: 127-136, 2019

The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors

Open access
Eur Psychiatry  **58**: 1-9, 2019

**Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: Understanding negative symptom scores in schizophrenia**

Neuropsychopharmacol s41386-019-0363-2, published online 05 March 2019

**Mania**

The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial

Bipolar Disord  **17**: 63-75, 2015

Cariprazine in the treatment of acute mania in bipolar I disorder: A double-blind, placebo controlled, phase III trial

J Affect Disord  **174**: 296-302, 2015

Efficacy and safety of low- and high-dose cariprazine in patients with acute and mixed mania associated with bipolar I disorder

J Clin Psychiatry  **76**: 284-292, 2015

Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials

Vieta E, Durgam S, Lu K, Ruth A, Debelle M, Zukin S
Eur Neuropsychopharm  **25**: 1882-1891, 2015

Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies

Earley W, Durgam S, Lu K, Debelle M, Laszlovszky I, Vieta E, Yatham LN
J Affect Disord  **215**: 205-212, 2017

The safety and tolerability of cariprazine in patients with bipolar I disorder: A 16-week open-label study

J Affect Disord  **225**: 350-356, 2018

Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder

J Affect Disord  **226**: 239-244, 2018

**Schizophrenia & Mania**

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis

Int J Clin Pract  e13037, 2017
**Bipolar Depression**

An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression


**Cariprazine Treatment of Bipolar Depression: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study**


*Am J Psychiatry* in press, 2019

**Major Depression add-on**

Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult MDD patients


Efficacy of adjunctive low-dose cariprazine in major depressive disorder: A randomized, double-blind, placebo-controlled trial

Fava M, Durgam S, Earley W, Lu K, Hayes R, Laszlovzky I, Németh G

*Int Clin Psychopharmacol* 33: 312-321, 2018

Cariprazine augmentation to antidepressant therapy in major depressive disorder: Results of a randomized, double-blind, placebo-controlled trial

Earley W, Guo H, Németh G, Harsányi J, Thase M

*Psychopharmacology Bulletin* 48: 62-80, 2018

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder

Vieta E, Earley WR, Burgess MV, Durgam S, Chen C, Zhong Y, Barabássy Á, Németh G

*Int Clin Psychopharmacol* 34: 76-83, 2019

**Human Pharmacokinetic**

Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [11C]-(+)-PHNO


*Psychopharmacology* 233: 3503-3512, 2016

Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment)


**Health Technology Assessment (HTA)**

Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone


Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia
Health Policy Tech published on line, 2019

General

Cariprazine – a milestone of the Hungarian drug research and unique possibility for the treatment of predominant negative symptoms of patients with schizophrenia.
A new chemical entity, developed by Gedeon Richter Plc. in Hungary received market authorization approval from FDA in schizophrenia and bipolar mania indications (Published in Hungarian with English abstract)
Laszlovszky I, Németh G
Gyógyszerészet 59: 643-646, 2015